Introduction
The irradiation of cellular blood components with either g-rays or X-rays is an established practice to prevent the development of transfusion-associated (TA)-GVHD in immunosuppressed patients, fetuses and very premature newborns, as well as in patients who have an increased likelihood of possessing one HLA haplotype for which the blood component donor is homozygous (for example, donations from family members and matched plt transfusions). TA-GVHD results from donor T lymphocytes present in transfused cellular blood components proliferating and destroying susceptible tissues and organs in the recipient. This disease has a reported mortality greater than 90%, presumably because the transfused lymphocytes' attack on the recipient's BM is intensely myelosuppressive. Shimoda 1 first published a case of TA-GVHD when he reported a patient with 'post-operative erythroderma,' which was later understood to be a form of TA-GVHD. The initial report of recognized TA-GVHD in 1965, noted the occurrence of hepatomegaly and fatal aplastic anemia in two infants treated with 'fresh blood. ' 2 Subsequently, TA-GVHD was recognized in immunocompromised patients who had received intensely myelosuppressive or myeloablative therapy. [3] [4] [5] [6] In addition, the disease has occurred in immunocompetent individuals who received a cellular blood component from a donor homozygous for an HLA haplotype for which the recipient is heterozygous. Such a situation is more likely to occur in populations with a high degree of HLA homogeneity, such as Japan and Israel, or as a result of a donation from one family member to another. 7 In contrast to TA-GVHD, hematopoietic SCT-related GVHD, is caused by transplanted cells attacking recipient tissues and organs other than the marrow. Until recently, irradiation has been the only established method of preventing TA-GVHD. A recent US Department of Health and Human Services report estimated that a total of B2.3 million blood components were irradiated in the United States in 2006, a number comparable to 2004. 8 The approximate number of components irradiated and the per cent these represent of total transfused components are shown in Table 1 .
The problems and challenges of blood component irradiation
There are problems associated with the irradiation of blood components (Table 2) . If irradiation is performed in response to a specific physician's order, it will delay release of the blood product for transfusion by at least several minutes. Furthermore, as many irradiators can accommodate only one blood component at a time, if several orders are placed at about the same time, there can be additional delays. The latter poses a potential threat during urgent clinical situations. The most common irradiation source used in the United States is cesium-137. The Nuclear Regulatory Commission reports that there are 575 cesium source blood irradiators in the United States. 9 Irradiation devices have been reported to cost B$107 000, with average operating costs of B$9000 annually 10 and weighing 4000-5000 lb. 9 This weight limits their location to architecturally predetermined heavy weight-bearing areas within a hospital blood bank. Therefore, rearrangement of the laboratory workspace may be required before installation. These operating costs are driven, in part, by the need for periodic careful dosimetry validation and recalibration of irradiation time because of source decay. Another potential problem is the failure to irradiate a component when indicated owing to a physician's not placing an order, failure on the part of staff to comply with the order or device failure. (Single-use indicator labels that confirm that an adequate dose of irradiation has been delivered are available at additional expense and are widely used.) Furthermore, it is not entirely clear which patients require irradiated blood components or when the requirement ends. It is plausible that this product modification will not be ordered for a patient at risk. For example, the occurrence of TA-GVHD in patients receiving fludarabine was unexpected, and the prolonged effects of this drug on immune function create uncertainty as to how long component irradiation should be continued. 11 In addition, irradiation induces changes in erythrocytes, and posttransfusion 24-h red cell recovery is reduced, although long-term in vivo survival is not significantly affected. On account of this reduced post-transfusion recovery, the US Food and Drug Administration (FDA) has issued guidelines that limit the shelf life of RBC after irradiation to 28 days or the original outdate (42 days after collection), whichever is shorter. In addition, potassium leakage from irradiated red cells is significantly enhanced. 12 Although this results in only a small total amount of potassium infused into a recipient, the potential for adverse effects in neonates and infants has been considered. In this regard, some hospitals have implemented additional limits on the storage time for irradiated RBCs transfused into neonates, particularly in the setting of hyperkalemia and/or renal failure. Plts are not significantly affected by the irradiation doses used and retain the remainder of their 5-day shelf life following irradiation.
The cesium contained in blood component irradiators is highly soluble in water, and is dispersible in an aerosolized form, which presents safety and security concerns. After the terrorist events of 11 September 2001, the Nuclear Regulatory Commission issued security requirements for the protection of cesium source irradiators 'to reduce the risk of malevolent use and intentional unauthorized access to radioactive material.' 9 The elements of these security requirements include background checks; access controls; monitoring for, detection of and response to unauthorized access; and the tracking of shipments. Meeting these security requirements have placed added burdens on blood collection agencies and hospital blood banks.
Furthermore, it is not clear when, if ever, irradiation can be discontinued for a patient who has undergone hematopoietic cell transplantation. Most hospitals do not have the capacity to irradiate blood, necessitating irradiation at a blood collection agency once a patient has returned to his home community. This may cause delayed availability and additional expense.
Microbial risks of transfusion
At the doses currently used (25 Gy delivered to the central portion of the blood component), irradiation does not have an antimicrobial effect. Nonetheless, it is well recognized that blood transfusions pose risks of pathogen transmission 14 At a time when only 38% of the population is eligible to give blood, 15 there is a compelling need for alternative technologies to address the infectious risks of transfusion.
Pathogen reduction
In response to these infectious risks, pathogen reduction processes have been developed and proven to be effective at substantially reducing the microbial burden of blood components. [16] [17] [18] These processes have been shown to prevent lymphocyte replication, and, as discussed below, there is strong evidence that they prevent TA-GVHD, thereby precluding the need to identify susceptible patients and eliminating the expense and difficulties associated with irradiation of blood components. At present, no commercially available technology has been developed for the pathogen reduction of all blood components. Four processes (solvent detergent, methylene blue plus visible light, amotosalen plus UV light and riboflavin plus UV light) have received the CE Mark in Europe for plasma, and two of these (the amotosalen and riboflavin processes) have also received the CE Mark for plts (Table 3) . Amotosalen and riboflavin bind to nucleic acids and thereby prevent lymphocyte as well as microbial replication. These processes are performed at blood collection agencies, not hospitals, and therefore do not result in delay of blood availability. Blood components prepared using the different methods of pathogen reduction have been subjected to extensive study regarding their toxicologic properties and clinical efficacy. These have been reviewed by Prowse. 19 No pathogen reduction technology for RBC units is commercially available at the present time.
Pathogen reduction treatment for blood components is not currently available in the United States. The FDA has taken a cautious approach toward approving novel pathogen reduction methodologies. Their concerns have turned on the facts that these products would be used in a wide range of patients, including neonates, and that these processes require careful consideration regarding the efficacy of the methodologies against microbial pathogens, the efficacy of the treated product and the safety of the processes to handlers of the chemicals used, to the environment and to patients. In addition, the potential decreased efficacy could affect the blood supply and lead to increased patient exposures. 20 One discussant at a recent consensus conference on pathogen reduction suggested that pathogen reduction results in an additional cost of $100-165 per unit. 20 We believe that costs would decrease substantially with widespread implementation. Despite the aforementioned concerns, Alter 17 has pointed to a 'great potential risk in delaying implementation of pathogen reduction while waiting for absolute evidence and a perfect system being put into place.' The availability of blood components that have been subjected to these technologies in the European Union and elsewhere is in sharp distinction with their absence in the United States.
The processes using amotosalen or riboflavin have been shown to prevent lymphocyte replication and are used for TA-GVHD prevention in countries in which these technologies have been licensed. They are reviewed in more detail below.
INTERCEPT
One such process, the INTERCEPT Blood System (Cerus Corporation, Concord, CA, USA), uses a synthetic psoralen (Amotosalen HCl) that reversibly intercalates into the helical regions of DNA and RNA. On illumination with UVA light (320-400 nm), psoralens undergo a reaction with pyrimidine bases initially to form covalent monoadducts and subsequently to crosslink DNA. This treatment prevents the replication of nucleic acids, thereby providing Grass et al. 22 initially showed the efficacy of amotosalen treatment accompanied by UVA irradiation for inactivating T cells in plt concentrates. They detected amotosalen-DNA adduct formation, inhibition of PCR amplification of small genomic sequences, strong inhibition of IL-8 synthesis and a robust reduction of T-cell viability. The most important of these studies involved the demonstration of equivalence of the INTERCEPT process to g irradiation for inactivation of 410 5 T-cells using the validated clonal T-cell proliferation assay as used to establish FDA guidance for 2500 cGy to prevent TA-GVHD. 23 Subsequently, Grass et al. showed that photochemical treatment with amotosalen and UVA irradiation prevented TA-GVHD in vivo using a murine transfusion model. 24 They concluded that this treatment is an effective alternative to g irradiation for the prevention of TA-GVHD. Truitt et al. compared the incidence of TA-GVHD after transfusion of INTERCEPT plts prepared with no g irradiation with that of g-irradiated plts for 166 patients at risk for TA-GVHD. In this study, no cases of TA-GVHD were identified in recipients of either g-irradiated or INTERCEPT plts. Cazenave et al. 31 have recently reported the efficacy of non-irradiated INTERCEPT plts in 699 hematologyoncology patients in Alsace, France. They did not observe any TA-GVHD. Osselaer et al. 32 reported on surveillance for TA-GVHD in 76 hematopoietic SCT patients transfused as a part of routine clinical practice over a 3-year period with non-irradiated INTERCEPT plts. No patient developed evidence of TA-GVHD.
Two large hemovigilance studies of more than 12 000 transfusions to 2050 patients, in which with the INTER-CEPT process was used in place of g irradiation, have been conducted without reported TA-GVHD. 33, 34 Specifically, Osselaer et al. 33 reported a prospective safety study of 5106 transfusions of plts prepared with the INTERCEPT process in five European sites, as used in routine clinical care. The INTERCEPT process was used in place of g irradiation for the prevention of TA-GVHD in all but one site. Osselaer et al. also reported on an expanded hemovigilance program regarding the safety of an additional 7437 transfusions of plts prepared with the INTER-CEPT process. In six of eight sites, INTERCEPT was used in place of g irradiation for the prevention of TA-GVHD. 34 Both of these studies were designed to measure acute transfusion reactions, and did not address the development of TA-GVHD; however, as noted in both studies, a majority of patients received repeated transfusions of INTERCEPT plts. These two reports document the widespread practice in Europe of not irradiating plts treated with the INTERCEPT process that are transfused to immunosuppressed patients. Specifically, since October 2003, at the Mont-Godinne blood center in Belgium, more than 15 000 non-irradiated INTERCEPT-treated apheresis plts have been provided to patients, including B150 patients who have received hematopoietic SCT. No instance of TA-GVHD has been reported to the national hemovigilance system or to the blood center. (JC. Osselaer, personal communication) Also, in the Alsace region of France, since July 2006, the INTERCEPT system has been used for all plt transfusions (435 000 doses, 40% apheresis and 60% buffy coat) without g irradiation. The hemovigilance system has not reported any TA-GVHD to date (Jean-Pierre Cazenave, MD, personal communication).
As 
Mirasol
Another process, Mirasol Pathogen Reduction Technology, uses riboflavin with UV illumination. Exposure of riboflavin to a UV light source (265-370 nm), when it is associated with nucleic acids, leads to a reaction that induces the oxidation of guanine residues and strand breaks resulting in irreversible nucleic acid damage. 35 This process has been shown to be highly effective at reducing the risk of transfusion-transmitted microbial infection. 18 Intriguingly, Mirasol treatment has also been shown to prevent alloimmunization by plt transfusion in rats. 36 The Mirasol System has been shown to functionally inactivate WBC in blood components. Fast et al. 37 showed that this process completely inhibited mononuclear cell (MNC) proliferation to phytohemagglutinin and other stimulatory agents. (They also noted that this treatment prevented the cells acting as APCs.) Fast et al. subsequently reported that Mirasol treatment of human MNCs before i.p. injection into mice completely prevented xenogeneic GVHD. 38 In these aforementioned studies, the MNCs were obtained from apheresis plts. Fast et al. 39 recently reported that exposure of whole blood units to the Mirasol process resulted in the inactivation of human peripheral blood MNCs in these units, using both in vitro assays and a xenoreactive murine model.
The Mirasol System has been used for pathogen reduction treatment of plts, plasma and whole blood. 18, 40 Its safety and efficacy for apheresis plts have been recently reported. 41 This process received the CE Mark approval for apheresis and buffy coat plts in 2007, and for fresh frozen plasma in 2008. The CE Mark includes approval for the inactivation of WBC in these products. A recent report presented its use in routine clinical practice. 42 At present, components treated with the Mirasol System are commercialized in certain European, Middle Eastern and African countries. As of this writing, a few thousand transfusions in these areas have been completed as a part of routine practice. Obviously, the more recent granting of the CE Mark for this system compared with the INTERCEPT system means that fewer transfusions have been performed, but several post-market studies are currently ongoing in centers using the product in the routine clinical setting. Data from this work are expected to be available in the coming year.
It is of interest that four of the six Mirasol System clinical trial sites in France dropped g irradiation during the trial for products treated with Mirasol. Overall, B70% of patients who were transfused with control products received g-irradiated components. (R. Goodrich, CaridianBCT Biotechnologies, personal communication). At present, of the sites using the Mirasol System for routine clinical practice, several are not g-irradiating components that would otherwise undergo this treatment.
Future considerations
Despite the remarkable advances in reducing transfusiontransmitted diseases, there is a continuing risk of microbial contamination of blood components. Recently, established and emerging infectious agents have been well documented to be transmitted by blood component transfusion. There is a compelling need for safe and effective pathogen reduction technologies applicable to blood transfusion practice. Clearly, enormous progress has been made for plts and plasma, although at present there is no clinically available pathogen reduction process for RBCs. Obviously, for universal microbial reduction, the availability of pathogen-reduced red cell components will be necessary. The same holds true for the elimination of component irradiation to prevent TA-GVHD.
Given the availability of two well-developed and highly tested pathogen reduction technologies, it is arguably feasible for countries that have not yet introduced them to do so now. Resources could then be concentrated on developing pathogen reduction for RBCs. 17 Although the cost of pathogen reduction has been raised as an issue, its implementation for all blood components could increase the availability of blood for transfusion owing to a relaxation of some donor qualification standards (for example, deferral for travel to malaria-endemic areas). Implementation could also lead to a reduction in costs required for other activities, including some donor-infectious disease testing (for example, Chagas disease, West Nile virus, CMV and syphilis) and blood component irradiation.
Conclusion
The development of pathogen reduction technologies has felicitously provided for the inactivation of MNCs that cause TA-GVHD. The large and growing experience in European and other countries with the use of the INTERCEPT and Mirasol Systems for non-irradiated blood component transfusion to immunosuppressed patients provides compelling evidence for the clinical efficacy of these technologies to prevent TA-GVHD. The commercial availability of these systems or other safe and effective pathogen reduction technologies, as well as their applicability to RBCs in the United States, would address a large number of challenging issues and expensive strategies related to blood donor history screening and infectious disease testing, as well as to the difficulties and expenses associated with the irradiation of blood components.
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